SRX246

SRX246
	File:SRX246.svg
Systematic (IUPAC) name
	(R)-4-([1,4'-bipiperidin]-1'-yl)-4-oxo-2-((3S,4R)-2-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)-4-((E)-styryl)azetidin-1-yl)-N-((R)-1-phenylethyl)butanamide
Identifiers
CAS Number	512784-93-9
ATC code	None
Chemical data
Formula	C42H49N5O5
Molecular mass	703.88 g/mol
	SMILES O=C1[C@@H](N2C(OC[C@@H]2C3=CC=CC=C3)=O)[C@@H](/C=C/C4=CC=CC=C4)N1[C@@H](C(N[C@H](C)C5=CC=CC=C5)=O)CC(N6CCC(N7CCCCC7)CC6)=O ;
	InChI InChI=1S/C42H49N5O5/c1-30(32-16-8-3-9-17-32)43-40(49)36(28-38(48)45-26-22-34(23-27-45)44-24-12-5-13-25-44)46-35(21-20-31-14-6-2-7-15-31)39(41(46)50)47-37(29-52-42(47)51)33-18-10-4-11-19-33/h2-4,6-11,14-21,30,34-37,39H,5,12-13,22-29H2,1H3,(H,43,49)/b21-20+/t30-,35-,36-,37-,39+/m1/s1 ; Key:FJUKOXWSIGULLE-JVOQCOEYSA-N ;

SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V_1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders.^[1]^[2]^[3] It is an azetidinone derivative, and was developed from LY-307174 as a lead compound.^[4] A phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder is ongoing.^[5] It is also being studied for the treatment of post-traumatic stress disorder.^[6]

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.